Clinical Trials Logo

Filter by:
  • None
  • Page [1]
NCT ID: NCT03427190 Recruiting - Suicide Attempt Clinical Trials

Suicide Prevention Algorithm in the French Overseas Territories

Start date: October 9, 2017
Phase: N/A
Study type: Interventional

In France, suicide behaviours are a major public health concern that triggered the creation in 2013 of a National Observatory of Suicide. In continental France, the "Algos" protocol was found to be effective for the prevention of suicide attempts reiterations. This protocol is based on a procedure that keeps telephone and postal contacts with the suicide attempter and allows, via an algorithm, to assess the risk of suicide attempt recurrence, in order to intervene if necessary. Nevertheless, Algos does not involve primary care health practitioners, who could add a substantial additional efficacy, especially if they intervene downstream and in supplement to Algos. In addition, this kind of protocol has never been evaluated in the French overseas territories.

NCT ID: NCT03368300 Recruiting - Clinical trials for Atypical Parkinsonism

Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans

Start date: August 3, 2012
Phase: N/A
Study type: Interventional

The primary aim of this study is to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana.

NCT ID: NCT03306251 Recruiting - Clinical trials for Mother to Child Transmission of HIV

National Cohort of Children Born to HIV-positive Mothers

Start date: June 2005
Phase: N/A
Study type: Observational

The purpose of this study is to provide a surveillance system to monitor changes in the rate of mother to child HIV transmission and preventive practices in France and especially to identify the occurrence of toxicity in children exposed perinatally to antiretroviral drugs.

NCT ID: NCT02516579 Active, not recruiting - Sickle Cell Disease Clinical Trials

European Sickle Cell Disease Cohort - Hydroxyurea

Start date: January 2009
Phase: N/A
Study type: Observational

In the context of the Risk Management Plan (RMP), as requested from Addmedica by the EMEA, to collect information about long-term safety of Siklos® (hydroxycarbamide) when used in current practices for the prevention of symptomatic vaso-occlusive complications in patients with Sickle Cell Disease.